Apollomics Inc. Warrant
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, … Read more
Apollomics Inc. Warrant - Asset Resilience Ratio
Apollomics Inc. Warrant (APLMW) has an Asset Resilience Ratio of 10.40% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Apollomics Inc. Warrant's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Apollomics Inc. Warrant's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.76 Million | 10.4% |
| Total Liquid Assets | $5.76 Million | 10.40% |
Asset Resilience Insights
- Moderate Liquidity: Apollomics Inc. Warrant has 10.40% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Apollomics Inc. Warrant Industry Peers by Asset Resilience Ratio
Compare Apollomics Inc. Warrant's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Apollomics Inc. Warrant (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Apollomics Inc. Warrant.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 10.40% | $5.76 Million | $55.39 Million | -18.29pp |
| 2022-12-31 | 28.69% | $21.94 Million | $76.47 Million | -9.99pp |
| 2021-12-31 | 38.68% | $47.74 Million | $123.44 Million | +24.71pp |
| 2020-12-31 | 13.97% | $23.74 Million | $169.94 Million | -- |